Adlai Nortye Group (ANL) vs Climb Bio (CLYM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Adlai Nortye Group (ANL) has outperformed Climb Bio (CLYM) over the past year, gaining 533.3% versus a gain of 440.6%. Adlai Nortye Group is the larger company by market cap ($550.6 million vs $539.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANL | CLYM |
|---|---|---|
| Share price | $8.55 | $9.19 |
| Market cap | $550.60M | $539.80M |
| 1-day change | -5.63% | -0.97% |
| YTD return | +502.11% | +129.75% |
| 1-year return | +533.33% | +440.59% |
| 5-year return | — | -33.21% |
| EPS (TTM) | $-0.66 | $-0.81 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-51.87M | $-59.85M |
| 52-week high | $17.25 | $18.33 |
| 52-week low | $0.879 | $1.64 |
| Distance from 52-week high | -50.43% | -49.86% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +245.03% | +209.03% |
| Average volume | 244.74K | 1.38M |
| Shares outstanding | 58.73M | 58.74M |
| Employees | 109 | 28 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANL has outperformed CLYM by 92.7 percentage points over the past year.
About Adlai Nortye Group
ANL stock →Adlai Nortye Group Ltd., a clinical-stage biopharmaceutical company, engages in the discovery and development of cancer therapies. The company's pipeline centers on RAS-targeting therapies and next-generation cancer immunotherapies.
Health Care · Biotechnology: Pharmaceutical Preparations · 109 employees
About Climb Bio
CLYM stock →Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 28 employees
ANL vs CLYM FAQ
Which is bigger, Adlai Nortye Group or Climb Bio?
Adlai Nortye Group (ANL) is larger, with a market capitalization of $550.60M compared with $539.80M for Climb Bio (CLYM).
Which stock has performed better over the past year, ANL or CLYM?
ANL returned +533.33% over the past 12 months, compared with +440.59% for CLYM (price return, excluding dividends). Past performance does not predict future results.
Are Adlai Nortye Group and Climb Bio in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.